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1. Introduction 
Helicobacter pylori infects about 50% of the world’s population and is a major cause of 
chronic gastritis, is strongly associated with the development of gastric and duodenal ulcers 
and has been linked with gastric adenocarcinoma and B-cell mucosa-associated lymphoid 
tissue lymphoma [1, 2].  
H. pylori Infection results in a sequence of events, ultimately resulting in the development of 
some gastrointestinal disorders. The sequence was first suggested by Correa et al. in 1975 
and has since been supported by many other studies. Colonization of the gastric mucosa by 
H. pylori first lead to the induction of an inflammatory response, predominantly by Th1  
(T helper cells type 1). The initial acute gastritis is followed by active chronic gastritis, which 
lasts for life if the infection is not treated. Nevertheless, H. pylori-positive subjects are mostly 
unaware of this inflammation due to the lack of clinical symptoms. The Th1 response results 
in epithelial cell damage rather than in the removal of H. pylori because H. pylori is not an 
intracellular pathogen. The ongoing presence of H. pylori thus causes a lifelong 
proinflammatory response coupled to cellular damage and initiates the histological cascade. 
The continuous production of reactive oxygen species that results from the ongoing 
inflammation can result in DNA damage, thus inducing the multiple mutations thought to 
be required for initiation of the cancer cascade depicted in Figure 1 (3, 4). 
Among the new methods of magnifying endoscopy, a prototype of endocytoscopy 
developed by Olympus was used for ex vivo visualization of Helicobacter pylori on 
experimentally infected gastric biopsies. Moving bacteria were observed at 1100× 
magnification, giving hope for a possible direct detection during endoscopy. Kim et al. also 
used magnifying endoscopy on 103 patients to classify the gastric surface according to four 
patterns: flat, irregular, papillary or nonstructured, which were then compared to the 
updated Sydney System for histologic gastritis. Histologic gastritis was found in 91% of the 
biopsy sections with a nonflat type, and among them, 96% were confirmed to harbor H. 
pylori infection. In another study, the magnified endoscopic findings in the gastric body 
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were classified into four patterns and then correlated with histology results. Type 1 pattern 
corresponded to normal gastric mucosa, types 2 and 3 to H. pylori -infected mucosa and type 
4 to atrophy. The sensitivity and specificity for these endoscopic findings were 92.7% and 
100% for type 1, and 100% and 92.7% for types 2 and 3 together, respectively (5). 
 
      Normal mucosa
Chronic active gastritis
      Gastric atrophy
 Intestinal metaplastia
          Dysplasia
       Gastric cancer
H. pylori
imunne response, diet
gastrin, host genetics
Achlorhydia,
carcinogens
 
Fig. 1. Model representing the role of H. pylori and other factors in gastric carcinogenesis, 
based on the cascade proposed by Correa et al (3, 4) 
2. H. pylori detection 
Various diagnostic assays for the detection of an H. pylori infection are available. 
Histological detection and culturing of the pathogen are gold standard, which require 
invasive gastroduodenoscopy to obtain gastric biopsy specimens. In the last decade, 
noninvasive approaches, such as serological detections, the [13C] and [14C]urea breath test 
(UBT), and detection H. pylori antigen or DNA in feces, helped and improved the evaluation 
of H. pylori infection status in patients. Because of low sensitivities of most serological assays 
for younger than 12 years of age patients, they are not suitable for pediatric. The UBT is a 
well-established noninvasive diagnostic assay and gives excellent performance for both 
adults and children, but its specificity decreases for infants and young children and need. In 
addition, the performance of UBT with infants and young children requires trained staff for 
air sampling with a face mask, and the test also requires expensive instruments, such as an 
isotope ratio mass spectrometer or an infrared isotope ratio spectrometer. Enzyme 
immunoassays (EIAs) for the identification of H. pylori antigens in fecal specimens 
circumvent these difficulties. EIAs based on monoclonal antibodies have shown consistent 
excellent results, with very high sensitivities and specificities for both adults and children. A 
major disadvantage of all the noninvasive tests described above is their inability to provide 
information on the susceptibility or resistance of H. pylori to antibiotics [2]. 
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Methods 
Sensitivity and 
Specificity 
Typical  
application 
Histology >95% 
Gold standard in 
routin hospital 
diagnostics 
Biopsy 
culture 
>95% 
Alternative gold 
standard 
Invasive 
methods 
RUT >90% 
Cost-effective and 
rapid test 
UBT >95% 
Alternative gold 
standard 
Fecal 
antigen 
>90% 
Not widely used 
yet 
Noninvasi
ve 
methods 
Serology 80-90% 
Mainly used for 
epidemiological 
studies 
Table 1. Non-PCR base diagnosis of H. pylori infection (3) 
3. Macrolide resistance 
H. pylori infection can be cured by antibiotics, however the ideal anti-H. pylori treatment has 
yet to be found. Many factors have been implicated in treatment failure, including 
ineffective penetration of antibiotics into the gastric mucosa, antibiotic inactivation by low 
gastric pH, lack of compliance, and emergence of acquired antibiotic resistance by H. pylori. 
Despite the success of the current anti-Helicobacter therapies, it is suggested that eradication 
rates among patients with gastritis are lower than among patients with peptic ulcer disease, 
with the causes of this phenomenon still being the subject of speculation [6].  
The macrolide class of antimicrobial agents is over 30 years old and is still at the forefront of 
antimicrobial therapy as well as drug discovery and development. Clarithromycin is a 
recently approved 14-membered macrolide with increased stability in acid and improved 
pharmacokinetics, including the appearance of a microbiologically active metabolite in 
humans. Clarithromycin possesses broad-spectrum antimicrobial activity, inhibiting a range 
of gram-positive and gram-negative organisms, some anaerobes, and atypical pathogens, in 
many cases with greater in vitro activity than erythromycin [7]. 
Clarithromycin is a semi-synthetic macrolide antibiotic. Chemically, it is  
6-0-methylerythromycin. The molecular formula is C38H69NO13, and the molecular weight is 
747.96 (Figure 2). Clarithromycin is a white to off-white crystalline powder. It is soluble in 
acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in 
water. 
Currently, a seven-day, triple-drug regimen has been recommended as one of the first-line 
therapies for H. pylori management. This treatment includes omeprazole (a proton-pump 
inhibitor), clarithromycin, and amoxicillin or metronidazole [2, 8]. However, this therapy is 
being investigated because of increased eradication failures due to the prevalence of 
clarithromycin resistant H. pylori infections. Many studies have shown that between 0–50% 
of H. pylori isolates were clarithromycin resistant, which leads to a need for long term 
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Fig. 2. The structural formula of clarithromycin 
assessment of the efficacy of clarithromycin in the triple-drug regimen. It is well known that 
the abuse of macrolide antibiotics including clarithromycin might lead to clarithromycin 
resistant forms of H. pylori [8]. Clarithromycin is a bacteriostatic antibiotic, which belongs to 
a group of macrolides bound to peptidyltransferase loop of domain V and VI of the 23S 
rRNA molecule (Figure 3 and 4). This binding interferes with protein elongation, and thus 
effectively blocks bacterial protein synthesis.  
The antibacterial activity of clarithromycin is similar to that of other macrolides, but 
clarithromycin is better absorbed in the gastric mucus layer, more acid-stable, and therefore 
more effective against H. pylori. Resistance to clarithromycin is thought to develop when 
substitutions in one nucleic acid at or near this binding site on the ribosome prevent the 
drug from binding, thereby making it ineffective [9]. Mutations A2144G, A2143G, A2142G 
and A2143C are the most often observed and reported by investigators, other mutations 
such as A2142C, A2115G, G2141A, A2142T and T2717C have been described but appear to 
be rare in peptidyltransferase [10, 11]. 
4. Detection of clarithromycin resistance 
Many diagnostic assays have been developed for Helicobacter pylori: culture, histology, rapid 
urease test, urea breath test, serology, stool antigen test, and molecular-based tests [2, 5, 10, 
11, 15]. Culture has the great advantage of permitting subsequent determination of the 
antimicrobial susceptibility of the strain isolated, in particular to macrolides. However, 
disadvantages of culture include special conditions for specimen transportation, the use of 
complicated media with special conditions for maintenance, the need for special incubation 
conditions, and the length of time necessary to obtain a result [10]. In routine practice the 
detection of clarithromycin resistance is mainly based on phenotypic methods performed 
after culture: agar diffusion for the E-test or the agar dilution method, which is considered 
the reference; however, these methods are time-consuming [16]. 
The association between point mutations in the 23S rRNA gene and macrolide resistance in 
H. pylori potentially provides a new approach for diagnosing macrolide resistant H. pylori 
strains [9]. Numerous molecular-based methods are now available to assess clarithromycin 
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Fig. 3. Model of domain V and VI of 23S rRNA from E. coli, (12 , 13) 
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in H. pylori, such as PCR-RFLP, PCR-OLA, PCR-DEIA, PCR- LiPA, PCR-PHFA, 3M-PCR, 
real-time PCR, FISH, FRET, DNA sequencing by conventional and real-time 
(pyrosequencing) techniques [2, 9-11]. Most assays are polymerase chain reaction (PCR)-
based using different methods to study the amplicons. The PCR-based molecular techniques 
are quicker than microbiological susceptibility testing, and more importantly, they can be 
performed directly on gastric biopsies and gastric juice [9].  
 
 
Fig. 4. A view into the macrolide-binding pocket in E. coli highlighting the specific geometry 
of the 2611–2057 base pair. H bonds are shown as dotted lines. The macrolide-binding 
pocket is located at the upper part of the ribosomal peptide exit tunnel, at a distance from 
the peptidyl transferase center that allows the accommodation of polypeptides of 5–6 
residues. It is formed mainly by 23S rRNA domain V nucleotides, among which A2058 and 
A2059 play a prominent role in binding, selectivity, and resistance. (14) 
A PCR-based approach to diagnostic testing has the advantage over existing non-culture-
based tests in that it is simple to perform and can provide additional genotypic information 
about the infecting strain, including markers associated with antibiotic susceptibilities. In 
addition, although the initial cost of equipment is high, the cost of reagents and 
consumables for each test is extremely low in comparison with corresponding costs for other 
methods such as the urea breath test and stool antigen test [17]. Great advantage of PCR is 
that it does not require viable bacteria. The transport conditions are thus not as critical as 
they are for culture, and shipment costs are cheaper. The cost of the reagents necessary for 
our technique is reasonable: $6.20 for H. pylori detection only and $8.60 for detection and 
clarithromycin susceptibility testing. By microbiological techniques, detection is cheaper, 
$1.70, but the price of detection with clarithromycin susceptibility testing by E-test, $6.90, is 
comparable to that of PCR [10]. Nested PCR generally increases sensitivity but also has a 
high risk of contamination. Real-time PCR has several advantages over conventional PCR, 
such as short working time, high specificity, and low risk of contamination. Thus far, some 
studies used real-time PCR targeting either ureC or 16S rRNA and 23S rRNA for the 
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quantitative detection of H. pylori in gastric biopsies [11]. FISH allowed simultaneous 
detection of H pylori and the point mutations. Also, FISH could be directly applied to 
formalin fixed tissue sections without extensive preparation of nucleic acid. Another 
advantage of this technique compared with PCR based systems became obvious when 
mixed strains and tissue sections harboring more than one H. pylori strain were examined. A 
mixed culture cannot be unequivocally differentiated from a strain carrying two different 
rRNA operons by restriction enzyme analysis or filter hybridization; this can be done easily 
by whole cell hybridization technology [18]. PCR-RFLP has some disadvantage than other 
PCR base techniques including: i: when multiple strains are present in one sample, PCR-
RFLP technique can not able to identify genotypes that has low concentration, ii: PCR-RFLP 
technique can not able to detect two mutations A2144G and A2143C, iii: Mixed populations 
containing a resistant strain associated with a susceptible strain are difficult to detect by 
PCR-RFLP. The resistant strain is often well detected because the mutation conferring 
resistance produces a restriction site that results in a new band on the electrophoresis 
profile. However, the uncut fragment corresponding to the susceptible clone is usually not 
taken into consideration. The uncut fragment is indeed more often attributed to an 
incomplete restriction than to a mixed population. Even for pure resistant strains, a band 
corresponding to the uncut fragment of DNA is sometimes still present on the electrophoresis 
profile due to partial restriction. Thus, a mixed population containing a susceptible strain 
associated with a resistant strain is detected as a single resistant strain [19]. 
A TaqMan probe is a short oligonucleotide (DNA) that contains a 5' fluorescent dye and 3' 
quenching dye. To generate a light signal (i.e., remove the effects of the quenching dye on 
the fluorescent dye), two events must occur. First, the probe must bind to a complementary 
strand of DNA. Second, Taq polymerase, the same enzyme used for the PCR, must cleave 
the 5' end of the TaqMan probe (5' nuclease activity), separating the fluorescent dye from the 
quenching dye (Figure 5) (20). 
 
  
Fig. 5. Schematic model for TaqMan probe technology 
Culture has the great advantage of permitting subsequent determination of the antimicrobial 
susceptibility of the strain isolated, in particular to macrolides. However, disadvantages of 
culture include special conditions for specimen transportation, the use of complicated media 
with special conditions for maintenance, the need for special incubation conditions, and the 
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length of time necessary to obtain a result [10]. Low bacterial density and a patchy 
distribution of the pathogen may have been the reasons for the negative culture and 
histology results. This may also be true for the patient determined to be negative by the 
rapid urease test, histology, and culture but positive by both PCR assays in the biopsy and 
the stool specimen, thus resulting in a reduction of the PCR specificity to 98% [11]. Culture 
is only semiquantitative and is time consuming. Histology is also semiquantitative, but its 
accurateness is relatively weak because of great interobserver variation. Urea breath test has 
been shown to be uncorrelated to culture-determined bacterial density [10]. 
5. Epidemiology of clarithromycin resistance 
Resistance to clarithromycin is the main predictor of failure of eradication treatments 
including this compound. Because of an increased use of these macrolides, not only for H. 
pylori eradication, but also for the treatment of respiratory tract infections, the prevalence 
rate of resistant strains is increasing, and the detection of resistance is becoming of major 
importance. To render this detection process more effective, results must be available 
rapidly. 
Several studies have shown that the eradication of H. pylori plays an important role in the 
treatment of some gastrointestinal diseases and the results of all currently used tests for 
bacterial detection can be affected by the treatment [21]. Therefore, a growing attention has 
been assigned to H. pylori antibiotic susceptibility monitoring, due to the increasing 
prevalence of antibiotic resistance worldwide. Rates of clarithromycin resistance in H. pylori 
strains have been reported in France 21%, Spain 28.3%, Portugal 44.8%, Poland 23.5%, 
Mexico 21.6%, China 5%, Korea 16.7%, Italy 26.7% and Germany 47% [5, 15, 22-24]. A similar 
geographical distribution has been observed in Iran, with clarithromycin resistance values 
ranging from 21% [25] to 35.98% .This relevant discrepancy could be explained not only by 
the different geographic distribution of resistances, but also by the use of different 
methodologies to assess clarithromycin resistant status. For example, a study recently 
performed in the same geographic area (Shahrekord, Iran) has reported clarithromycin 
resistance rate 22.62% [26] distinctly lower compared with our present experience (35.98%). 
Nevertheless, it is possible that the different methods used (antibiogram vs. real-time PCR) 
could have played a role in these discordant data as bacterial culture is hampered by 
limitations, such as a low sensitivity, even in expert-hands [22]. 
Although H. pylori has two copy of 23S rRNA gene in own genome, but many authors 
suggested that more than one strain can present in one patient [11, 27-29]. Also many 
authors displayed multiple genotypes in one sample because: 1) A troubling aspect of 
resistance to some antibiotics by H. pylori is a phenomenon that has been given the name 
heteroresistance. This phenomenon has been previously observed for resistance to 
metronidazole [30]; 2) H. pylori is transformable bacterium and the transformation frequency 
for clarithromycin resistance of H. pylori was found to be approximately 2×10-6 
transformants per viable cell [31]; 3) More importantly, Taylor and et al. suggests that 
acquisition of antibiotic resistance could result from the horizontal transfer of clarithromycin 
resistance determinants from resistant cells to susceptible cells of the same strain, probably 
increasing the population of resistant strains. In addition, such genetic transfer could occur 
between different strains, since mixed infections with different H. pylori strains does occur in 
some individuals [31]. 
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Country Year Technique Sample No. Resistance rete Ref 
Australia 2004 Real-time PCR 92 24% 8 
France 1994-1999 E-test 150 21% 32 
France 1998 
Hybridization in 
Liquid Phase 
41 56% 33 
France 1999 
PCR-DNA Enzyme 
Immunoassay 
61 37.7% 21 
France 2000 E-test 61 18% 34 
France 2003 Real-time PCR 200 67% 11 
France 2003 Real-time PCR 196 18.5% 7 
France 2004-2008 Real-time PCR 126 20% 35 
Germany 2001 FISH 109 31.2% 36 
Germany 1999-2002 E-test 1233 20% 37 
Netherland 2001 RAPD-PCR 976 5.2% 8 
Italy 2003 PCR-RFLP 283 1.6% 12 
Italy 2003 PCR-RFLP & E-test 230 14% 38 
Ireland 2001 LiPA 50 26% 39 
Spain 2008 E-test 118 35.6% 40 
Brazil 2001 Agar Diliution 202 9.85% 41 
Brazil 2003 Agar Dilution 155 16% 3 
Mexico 1995-1997 E-test 195 24% 42 
Peru 1995 Egg Yolk Agar 18 50% 43 
Argentina 2000 PCR-RFLP 96 23.9% 44 
USA 1996 PCR-OLA 72 55% 45 
China 2001 Primer mismatch PCR 96 5% 16 
China 200-2009 Agar Dilution 293 8.6%-20.7% 46 
Japan 1998 Seminested PCR 85 9% 47 
Japan 1999 PCR-RFLP 79 6.3% 22 
Japan 2000 PCR-PHFA 412 22% 48 
Japan 2001 Real-time PCR 186 21.2% 49 
Japan 2001 PCR-RFLP 51 29% 50 
Malaysia 2005-2007 E-test 187 2.1% 51 
Indonesia 2006 Disk diffusion 126 27.8% 52 
Korea 2004 PCR-RFLP 114 20.2% 53 
Iran 2007 PCR-RFLP 263 22.6% 54 
Iran 2009 PCR-RFLP 200 23.78% 55 
Iran 2009 Real-time PCR 200 35.98% 55 
Iran 2008-2009 E-test 121 5% 56 
Tunisa 2005-2007 Real-time PCR 273 14.6% 57 
Cuba 2005 E-test 46 10% 58 
Table 2. Prevalence of clarithromycin resistance in the world. Comparison between date, 
technique and region 
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Currently, many research aims to evaluation of clarithromycin resistance in H. pylori were 
performed which showed variety of resistance rate around the world, due to 3 main reasons 
including differences in i: methods, ii: region and iii: date (Table 2). 
Many investigators were assessed clarithromycin resistance rate in Europe in 1994 to 2009. 
In these studies, clarithromycin resistance was more prevalent in France. Also, Fontana et al 
by PCR-RFLP method showed that clarithromycin resistance was more divers between 
north (1.6%) and south (14%) of Italy in 2003.  
In continent of America, clarithromycin resistance was varies between 9.8% in Brazil to 55% 
in USA. Less variety were observed in eastern Asia, by 20% to 27% resistance rate. In Iran 
(Middle East) with variety of customs, Kargar et al showed resistant rate of 23% and 36% in 
same geographic region in 2009 due to different methods including PCR-RFLP and real-time 
PCR assays respectively but, PCR-RFLP showed 22% and 23%resistance rate in 2007 and 
2009 respectively. Also more variation was observed in 2 near region with different customs 
and economic level, with 36% in low economic level and 5% in high economic level.  
6. Epidemiology of clarithromycin resistance mutations 
Many studies aim to assessment of clarithromycin resistance rate were preformed around 
the world. This studies showed A2144G > A2142G > A2143G > A2142C > A2143C order for 
clarithromycin resistance point mutations (Table 3). 
 
Researcher Country technique Mutations rate Ref 
Pina France Hybridization 
in Liquid Phase 
A2144G(56%) 
A2143G(35%) 
A2143C(9%) 
32 
Marais France 
PCR-DNA 
Enzyme 
Immunoassay 
A2144G(48%) 
A2143G(24%) 
A2143C(3%) 
21 
Russman Germany FISH 
A2144G(59%) 
A2143G(35%) 
A2143C(6%) 
36 
Maeda Japan 
Seminested 
PCR 
A2144G(87.5%) 
A2143G(12.5%) 
47 
Matsuok Japan PCR-RFLP 
A2144G(80%) 
A2143G(20%) 
22 
Matsumura Japan Real-time PCR 
A2144G(55%) 
A2143G(5%) 
49 
Kargar Iran PCR-RFLP 
A2143G(68.3%) 
A2142G(15.8%) 
54 
Kargar Iran Real-time PCR 
A2144G(5.7%) 
A2143G(37.1%) 
A2142G(28.6%) 
A2143C(21.4%) 
55 
Table 3. Prevalence of clarithromycin resistance point mutations 
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7. Problem statement 
Following the recognition of the important pathogenic role of H. pylori infection in the 
development of gastroduodenal diseases, there has been a continuous search for improved 
eradication therapy (Occhilini et al., 1997). H. pylori culture, as well as antimicrobial 
susceptibility studies is difficult to perform as well as labor intensive. Moreover, although 
the culture method allows antimicrobial susceptibility testing for several antibiotics, only 
the susceptibilities of macrolides and, in particular, of clarithromycin are really useful since 
the last is a major predictor of treatment failure. Therefore, detection of clarithromycin-
resistant H. pylori will facilitate the choice of an appropriate eradication regimen 
7.1 Aplication area 
The characterization of resistance mechanisms in H. pylori and their easy detection will 
facilitate the choice of appropriate treatment regimens and ultimately the control of 
infection. PCR-RFLP can be used directly with biopsy specimens, thereby avoiding the 
requirement for time-consuming culture-based methods. This is particularly important for 
patients in whom a first eradication attempt has failed. 
7.2 Material and methods 
Study design 
In order to assess the clarithromycin resistance rate, 23S rRNA point mutations responsible 
for clarithromycin resistance and effect of technique, region and date, 2 separate analyses 
were performed. 
7.3 Analysis 1 
Patients 
263 consecutive patients with dyspeptic symptoms attending the endoscopy center of the 
gastroenterology department of the Hajar Hospital, Shahrekord, Iran, were enrolled in this 
study from July to December 2008. Patient-reported symptoms and endoscopic findings of 
pathologist were recorded at the time of the consultation by the pathologist help, and these 
data were obtained retrospectively for analysis. The number of participants who were 
ineligible or declined participation in the study were not recorded. 
For the purpose of analysis, three global variables were created: 1) patient-reported included 
age, gender and symptoms, 2) clinical signs, and 3) clarithromycin resistance data. Patient-
reported symptoms included pain, anorexia, heaviness after meal, early satiety, nausea, 
vomiting and flatulence. Clinical signs were included gastric ulcer, gastric cancer, non-ulcer 
disease, gastic erosion, nodularity, gastritis and duodenit. All patients read and signed an 
‘informed consent’ form at the beginning of endoscopy declared their satisfaction for 
application of their anonymous data for research purpose.  
Three biopsy specimens were taken from antrum and corpus of each patient, using a 
disinfected endoscope. Biopsy samples were placed in 0.1 ml of sterile saline solution and 
sent to the Biotechnology research center of Shahrekord Azad University. A rapid test for 
the detection of urease activity was performed by Gastro Urease kit (Bahar-afshan, Iran) 
according to manufacturer's instructions. DNA was isolated from each tissue with a DNA 
extraction kit (DNPTM, CinnaGen, Iran) according to the manufacturer’s instruction and 
immediately used for molecular analysis. 
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Bacteria and culture conditions 
Biopsy samples were cultured on Brucella agar (Merck) supplemented with 7% fresh horse 
blood, vancomycin (6mg/L, Merck), trimethoprim (5mg/L, Merck) and amphotericin 
(2mg/L, Merck). For primary culture, plates were incubated at 37°C in a microaerophilic 
atmosphere (5% O2, 15% CO2, 80%N2) for 3 to 5 days. Strains were identified according to 
colony morphology, Gram staining and positive reactions with urease, catalase, and oxidase. 
The ureC gene (glmM) which encodes urease was used as a DNA target to confirm H. pylori 
strain. 
Antimicrobial susceptibility testing 
The susceptibilities of the H. pylori isolates to clarithromycin were examined by an agar 
dilution method according to CLSI (Clinical and Laboratory Standard Institute) protocol 
(32). Resistance breakpoint for clarithromycin was defined as the >4 µg/liter. 
Conventional PCR assays 
A PCR assay targeted at the ureC (glmM) gene of H. pylori was performed with specific 
primer (Table 4) in an eppendorf mastercycler gradient (eppendorf, Germany). Briefly, the 
23 µl PCR mixture, containing 1 µl of extracted DNA, 200 mM (each) deoxynucleoside 
triphosphates (dNTPs) (dNTP Mix, CinnaGen, Iran), 0.2 mM (each) primer (CinnaGen, 
Iran), 1.5 mM MgCl2, and 1 U of Taq polymerase (CinnaGen, Iran) in PCR buffer (CinnaGen, 
Iran), was held for 5 min at a denaturation temperature of 95°C, followed by 30 cycles of 1 
min each at a denaturation temperature of 95°C, an annealing temperature of 58°C, and an 
elongation temperature of 72°C and by 5 min at 72°C. The amplified fragment was visualized 
after electrophoresis on a 1.5% agarose gel stained with ethidium bromide. 
PCR-RFLP analysis 
A 1,400-bp fragment of the 23S rRNA gene was amplified with primers Cla-18 and Cla-21 
[44] (Table 3). PCR amplification of DNA was performed in a final volume of 24 µl PCR 
mixture, containing 2 µl of extracted DNA, 200 mM dNTPs, 0.2 mM (each) primer, 1.5 mM 
MgCl2, and 1 U of Taq polymerase in PCR buffer. Amplification was carried out in an 
eppendorf mastercycler gradient over 30 cycles, each for 1 min at 95°C, 1 min at 62°C, and 1 
min at 72°C. These cycles were performed after a denaturation of 5 min at 95°C and a final 
elongation step at 72°C for 5 min. The amplicon was digested with BsaI for 1 h at 37°C and 
MboII (Fermentas GMBH, Germany) for 1 h at 37°C to detect the restriction site occurring 
when the mutation was A to G transition at 2143 or 2142, respectively (Figure 5). The 
restriction products were analyzed by electrophoresis on a 2% agarose gel. 
 
 
Fig. 5. Schematic diagram for detection of nucleotide alterations of 23S rRNA by PCR-RFLP 
assays 
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7.4 Analysis 2 
Sample collection 
200 biopsy samples were obtained over a 6-month period (June 2009 to November 2009) 
from 200 dyspeptic patients referred for endoscopy at Hajar hospital in Iran. All patients 
read and signed an ‘informed consent’ form at the beginning of endoscopy declared they are 
satisfied with application of their anonymous data for research purpose. Every patient 
history sheet was examined in detail and clinical findings including demographic data were 
recorded.  The mean age of the patients was 52.5 years (range, 17 to 88 years), and 48.1% of 
the patients were men. Rapid urease test was performed with a Gastro urease kit (bahar-
afshan, Iran). DNA was isolated from each tissue with a DNA extraction kit (DNPTM, 
CinnaGen, Iran) according to the manufacturer’s instruction and immediately used for 
molecular analysis. Conventional PCR for detection of ureC gene and PCR-RFLP analysis for 
detection of point mutations were performed as in analysis 1. 
 
 
Fig. 6. PCR-RFLP patterns obtained after digestion with BsaI or MboII. BsaI cuts the PCR 
product of the wild-type sequence into two fragments of 1,000 and 400bp and that of the 
A2143G sequence into three fragments of 700, 400, and 300bp. MboII cuts the PCR product 
into two fragments of 700bp only when A2142G is present in the sequence: 1)A2142G 
positive control, 2)A2142G negative control, 3)A2142G positive strain, 4)A2143G positive 
control, 5)A2143G negative control, 6)A2143G positive strain 
Real-time (TaqMan) PCR assay 
The real-time PCR was performed by using primer pair HP23S-1 and HP23S-2 and modified 
probes Pwt, P44G, P43G and P43C that previously reported by Pina et al [33] and newly 
designed probe P42G according to 23S rRNA gene sequence (GenBank accession no. 
U27270) for identification of wild type, A2144G, A2143G, A2143C and A2142G genotypes 
respectively (Table 3). 
The real-time (TaqMan) PCR mixture was prepared until reaching a final solution of 25 µl 
containing 2 µl of extracted DNA, 200 mM dNTPs, 0.2 mM (each) primer HP23S-1 and 
HP23S-2, 0.1 mM probe Pwt, 0.2mM probe P44G, 0.1 mM probe P43G, 0.1 mM probe P43C 
and 0.75 mM probe P42G (Bioneer,Tokyo, Korea) (Table I), 1.5 mM MgCl2, and 1 U of Taq 
www.intechopen.com
 Gastrointestinal Endoscopy 
 
112 
polymerase in PCR buffer 1X. Real-time PCR analysis was performed with an Rotor-Gene 
6000 (Corbett Research, Australia). The conditions of PCR amplification were 95°C for 5 min 
and 45 cycles of 95°C for 30 s and 58°C for 40 s. All samples were repeated twice and 
positive and negative controls were enclosed in each assay. Data were analyzed with rotor-
gene 6000 software ver1.7 (Corbett research). In order to test the specificity of the primers 
purified DNA of non-H. pylori strains was also used as a template for PCR. 
Quantification real-time PCR 
In order to made standard serial dilution, standard density of bacteria was prepared. After 
DNA extraction, one 10-fold serial dilution of H. pylori DNA was made, with bacterial 
concentrations ranging from 5×102 to 5×107 bacteria per 1 µl. Bacterial quantification was 
performed by TaqMan probe technology of real-time PCR as described above. 
Statistical analysis 
Statistical analyses were conducted with chi-square using the SPSS for Windows (version 17; 
SPSS, Inc., Chicago, Illinois, USA). P-values less than 0.05 were taken to indicate statistical 
significance. 
 
Primer/Probe Sequence (5′→3′) Target 
HP-1 AAGCTTTTAGGGGTGTTAGGGGTTT 
HP-2 AAGCTTATTTCTAACGC 
ureC 
Cla-18 AGTCGGGACCTAAGGCGAG 
Cla-21 TTCCCGCTTAGATGCTTTCAG 
23S rRNA 
HP23S-1 CCACAGCGATGTGGTCTCAG 
HP23S-2 CTCCATAAGAGCCAAAGCCC 
23S rRNA 
Pwt Cy5-GGGGTCTTTCCGTCT-BHQ2 Wild type 
P44G TAMRA-GGTCCTTCCGTCTTG-Dabcyl A2144G 
P43G TET-GGTCTCTCCGTCTTG-Dabcyl A2143G 
P43C HEX-GGTCTGTCCGTCTTG-Dabcyl A2143C 
P42G FAM-GGTCTTCCCGTCTTG-Dabcyl A2142G 
Table 4. Oligonucleotides sequence used in this study 
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Fig. 7. Prevalence of patients reported symptoms in analysis 1 
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Gastritic Cancer
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Fig. 8. Prevalence of clinical signs in analysis 1 
8. Results 
8.1 Analysis 1 
Clinical features 
Abdominal pain was present in 76% of patients (200/263), dyspepsia in 8%(20/263), 
vomiting in 6%(16/263), heartburn in 6%(17/263), and weakness 4%(10/263). The main 
endoscopic findings were 36% gastritis, 13% duodenal ulcer, 10% gastric ulcer, 9% 
esophagitis, and 5% gastric cancer (Figure 7, 8).  
Culture, rapide urease test and PCR  
H. pylori could be cultured from 84 of 263 (32%) patients, while a positive RUT or PCR band 
was observed in 54%(143 of 263) and 85%(223 of 263) of patients, respectively. Of the 84 
patients with positive H. pylori culture 35/84 (41.7%) were males and 49/84 (58.3%) females. 
H. pylori was successfully cultured from 55 of 135 (41%) patients with non-ulcer dyspepsia 
and 29 of 62 (47%) with peptic ulcer (PU).   
When the PCR was regarded as the “gold standard” of H. pylori identification, the 
sensitivity, specificity, PPV and NPV of RUT were 61%, 87%, 96% and 29% respectively. But 
for culture method were 36.77%, 95%, 97% and 21.22% respectively [59]. 
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Fig. 9. Frequency of 23S rRNA mutations in analysis 1 (n=19) 
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Prevalence of clarithromycin resistance 
According to the agar dilution method, 19 of 84 (22.62%) cultured strains were resistant to 
clarithromycin. A 1.4kb fragment of the 23S rRNA gene could be amplified in all 19 strains. 
Furthermore, MboII cuts PCR products were obtained from 3 and BsaI cuts another 13 
amplified fragments of the resistant strains. In one strain, neither MboII nor BsaI was able to 
digest the amplicon. However, specially primed mismatched PCR yielded an amplicon, 
indicating that this strain had the A2142C mutation (Figure 9). No correlation was observed 
between the clarithromycin resistance, patient gender and clinical findings. 
8.2 Analysis 2 
Clinical features 
164 patients with median age of 51.5 ranged from 15 to 88 years. Pain was present in 103 
patient, nausea in 42, anorexia in 40, acid reflux in 33, heaviness after meal in 30, early 
satiety in 27, vomiting in 31 and flatulence in 42. The main endoscopic findings were 16 
gastric ulcer, 3 gastric cancer, 55 non-ulcer disease, 50 gastric erosion, 34 nodularity, 37 
gastritis and 3 duodenitis (Table 5).  
 
Age group Male Female Total 
10-20 6 (3.66) 4 (2.44) 10 (6.10) 
20-30 12 (7.32) 13 (7.93) 25 (15.24) 
30-40 13 (7.93) 15 (9.15) 28 (17.07) 
40-50 13 (7.93) 14 (8.54) 27 (16.46) 
50-60 10 (6.10) 11 (6.71) 21 (12.80) 
60-70 12 (7.32) 13 (7.93) 25 (15.25) 
70-80 9 (5.49) 6 (3.66) 15 (9.15) 
80-90 4 (2.44) 9 (5.49) 13 (7.93) 
Total 79 (48.17) 85 (51.83) 164 (100) 
Table 5. Distribution of H. pylori positive patients according to gender and age group 
(n=164) 
Detection of H. pylori directly in gastric biopsy samples 
RUT results showed that the 164 (82%) of the patients were H. pylori-positive. DNA samples 
derived from gastric biopsy samples of confirmed H. pylori-positive patients were positive 
by the diagnostic PCR assays for the ureC targets. The ureC PCR assay confirmed the 
presence of H. pylori in all of these 164 biopsy samples (100%) and generated the expected 
PCR product of 249 bp. 
PCR-RFLP 
Thirty-nine of 59 resistant strains detected by real-time PCR methods were detected by PCR-
RFLP and were distributed as follows: 15 A2143G and 15 A2142G single mutation, 6 wild 
type/A2143G, one wild type/A2142G and 2 A2143G/A2142G genotypes (Table 6). BsaI cuts 
the PCR product of the wild-type sequence into two fragments of 1,000 and 400bp and that 
of the A2143G sequence into three fragments of 700, 400, and 300bp. MboII cuts the PCR 
product into two fragments of 700bp only when A2142G is present in the sequence (Figure 
6). sensitivity and specificity of PCR-RFLP were 74.68% and 100% respectively when we 
PCR-RFLP was compared with real-time PCR. 
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Genotype 
Outcome sample (%)
Real-time-PCR PCR-RFLP 
105  (64.01) Wild Wild 
3 (1.83) A2144G Wild 
13(7.93) A2143G A2143G 
7(4.27) A2143C Wild 
Single 
genotype 
143 (87.19)
15(9.15) A2142G A2142G 
6(3.66) A2143G/Wild A2143G/Wild 
1(0.61) A2143C/Wild Wild 
1(0.61) A2142G/Wild A2142G/Wild 
1(0.61) A2143G/A2143C/Wild Wild 
1(0.61) 
A2144G/A2143G/A2143C/
Wild 
A2143G 
1(0.61) A2143G/A2143C A2143G 
1(0.61) A2143G/A2143C Wild 
1(0.61) A2143G/A2142G A2143G/A2142G 
1(0.61) A2143C/A2142G Wild 
1(0.61) A2143G/A2143C/A2142G A2143G/A2142G 
1(0.61) A2143G/A2143C/A2142G Wild 
Heteroresis
tance 
21 (12.81) 
 
5(3.05) Not Determined Wild 
Table 6. Frequency of H. pylori genotypes determined by real-time PCR and PCR-RFLP 
methods in analysis 2 (n=164) 
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Fig. 10. Graph obtained with real-time PCR for the susceptible and resistant strains isolated 
from different patients. CT for pure samples were less than 35 and CT of mix samples were 
between 35 and 40. (All graphs obtained by different probes are similar) 
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Disease 104 105 106 107 108 109 1010 1011 1012 Total 
Peptic Ulcer 1 (0.6) 0 (0) 7 (4.27) 4 (2.44) 2 (1.22) 1 (0.6) 0 (0) 0 (0) 0 (0) 15 (9.15) 
Gastric Cancer 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.6) 0 (0) 2 (1.22) 3 (1.83) 
Gastric Erosion 1 (0.6) 2 (1.22) 20 (12.19) 18 (10.98) 5 (3.05) 1 (0.6) 0 (0) 2 (1.22) 0 (0) 49 (29.88) 
Nodularity 2 (1.22) 4 (2.44) 13 (7.93) 11 (6.71) 3 (1.83) 0 (0) 0 (0) 0 (0) 0 (0) 33 (20.12) 
Gastritis 3 (1.83) 3 (1.83) 15 (9.15) 13 (7.93) 1 (0.6) 0 (0) 1 (0.6) 0 (0) 0 (0) 36 (21.95) 
Duodenitis 0 (0) 1 (0.6) 1 (0.6) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.83) 
Atrrophy 0 (0) 0 (0) 0 (0) 2 (1.22) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.83) 
Duodenit Ulcer 0 (0) 0 (0) 13 (7.93) 8 (4.88) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 22 (13.41) 
Table 7. Endoscopic finding and frequency of bacterial count of H. pylori positive patients 
(n=164) 
 
Symptoms 104 105 106 107 108 109 1010 1011 1012 Total 
Pain 3 (1.83) 9 (5.49) 42 (25.61) 32 (19.51) 6 (3.66) 2 (1.22) 2 (1.22) 2 (1.22) 1 (0.6) 99 (60.36) 
Nausea 3 (1.83) 1 (0.6) 20 (12.19) 13 (7.93) 3 (1.83) 0 (0) 0 (0) 1 (0.6) 1 (0.6) 42 (25.61) 
Anorexia 3 (1.83) 3 (1.83) 18 (10.98) 14 (8.54) 0 (0) 1 (0.6) 0 (0) 0 (0) 0 (0) 39 (23.78) 
Acid reflux 4 (2.44) 1 (0.6) 12 (7.32) 9 (5.49) 4 (2.44) 0 (0) 0 (0) 0 (0) 1 (0.6) 31 (18.90) 
Heaviness 
after meal 
1 (0.6) 3 (1.83) 9 (5.49) 12 (7.32) 3 (1.83) 0 (0) 1 (0.6) 0 (0) 0 (0) 29 (17.68) 
Early satiety 2 (1.22) 1 (0.6) 13 (7.93) 8 (4.88) 1 (0.6) 0 (0) 1 (0.6) 0 (0) 0 (0) 26 (15.85) 
Vomiting 3 (1.83) 2 (1.22) 12 (7.32) 10 (6.10) 1 (0.6) 0 (0) 0 (0) 0 (0) 1 (0.6) 29 (17.68) 
Flatulence 3 (1.83) 4 (2.44) 19 (11.58) 11 (6.71) 1 (0.6) 0 (0) 1 (0.6) 0 (0) 1 (0.6) 40 (24.39) 
Table 8. Interview data and bacterial count of H. pylori positive patients (n=164) 
Determination of the cut-off for the CT values 
The detection of fluorescence was realized in the different channels of the rotor-gene 
thermocycler during 45 cycles of amplification. Among the 164 biopsy specimens, a 
detection of fluorescence was positive in one of the different channels in 143 (87.2%) cases. 
Sixteen biopsy specimens displayed more than one CT values for mix genotypes. CT values 
ranged from 21.4 to 43.6. CT values less than 35 determined as pure sample DNA and CT 
between 35 and 40 indicate as mix DNA sample. Detection of fluorescence over 40 cycles 
might be false positive (Figure 10).  
Development of TaqMan real-time PCR 
Concerning amplification of H. pylori DNA obtained from a pure culture, linearity was 
achieved over a 5-log range of input DNA amounts, from  5×102 to 5×107 bacteria, with 500 
bacteria corresponding to 1000 23S rRNA gene copies given that there are two gene copies in 
the genome of H. pylori. PCR was also positive for 40 bacteria or 80 copies of the 23S rRNA 
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gene fragment. The amplification efficiencies obtained with DNA prepared from gastric 
biopsy specimens were identical to those obtained with DNA samples prepared from 
bacterial colonies. Thus, the sensitivity of our assay, for DNA samples prepared either from 
cultures or from gastric biopsy specimens, could quantitatively reach 400 bacteria or 800 
copies of the amplicon and qualitatively reach 40 bacteria or 80 copies. The reproducibility 
of our assay was evaluated with 10-fold serial dilutions of purified H. pylori DNA, with no 
significant difference between runs. 
Real-time PCR 
Bacterial clarithromycin resistance was assessed on 164 consecutive, H. pylori-positive 
patients. Overall, a clarithromycin susceptible was detected in 105 (64.02%) patients and 
clarithromycin resistance was detected in 59 (35.98%) which were identified as 4 (6.78%) 
A2144G, 26 (44.07%) A2143G, 15 (25.42%) A2143C and 20 (33.9%) A2142G point mutations. 
Purely resistant strains were detected in 38 (64.41%), while a mixture of resistant and 
susceptible (heteroresistant) bacterial strains were found in the remaining 16 (27.12%) cases. 
Genotype of 5 (8.47%) strains were not detected (Table 6) [60]. 
Quantification of bacterial density 
Quantification of different genotypes was directly performed on 159 DNA samples with 
defined genotype by using TaqMan real-time-PCR assay. The bacterial density by this 
technique could be evaluated for 159 H. pylori-positive patients and ranged from 1.53×104 to 
5.89×1012. In order to evaluate relationship between bacterial concentration and point 
mutations, samples divided in 9 groups between 1×104 to 6×1012, including 104, 105, 106, 107, 
108, 109,1010, 1011 and 1012 groups had 6, 11, 87, 59, 9, 2, 2, 2 and 2 samples respectively (Table 
7 and 8). 
 
Bacterial 
count 
Wild 
type 
A2144G A2143G A2143C A2142G 
104 1 0 2 2 1 
105 7 0 2 1 1 
106 39 4 18 12 14 
107 51 0 4 0 4 
108 9 0 0 0 0 
109 2 0 0 0 0 
1010 2 0 0 0 0 
1011 2 0 0 0 0 
1012 2 0 0 0 0 
Total 105 4 26 15 20 
Table 9. Distribution of 5 different genotypes based on their concentrations 
Statistical analysis 
Chi-square analysis revealed more relationship between gastritis and age group 30-40 
(p=0.007), NUD and 40-50 (p=0.001), early satiety and 10-20 (p=0.05), flatulence and 10-20 
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(p=0.038), vomiting and 20-30 (p=0.001), pain and 50-60 (p=0.003), heaviness after meal and 
50-60 (p=0.018), early satiety and 60-70 (p=0.05). 
Also statistical analysis revealed more relationship between wild type and 106 (p=0.00) and 
107 (p=0.00), A2144G and 106 (p=0.033), A2143G and 106 (p=0.005), A2143C and 106 (p=0.005) 
and A2142G and 106 (p=0.015) (Table 9) [61]. 
Also, results showed relation ships between Ages 10-20 and early satiety (p=0.05) and 
flatulence (p=0.038), 20-30 and vomiting (p=0.001), 50-60 and pain (p=0.003) and heaviness 
after meal (p=0.018) and 50-60 and early satiety (p=0.05). 
9. Conclusion 
In conclusion, we have developed a TaqMan real-time PCR assay that permits accurate, fast, 
and cost-effective detection of H. pylori directly from gastric biopsy specimens as well as 
detection of clarithromycin resistance. This PCR technique is a good candidate for 
automated real-time PCR methods allowing simple and rapid detection of H. pylori and its 
resistance to clarithromycin by clinical laboratories which do not practice H. pylori culture. 
Identification of sensitive and resistant strains by using PCR-RFLP method was based on the 
determination of resistant strains. Therefore, other resistant strains, which mutations cannot 
be identified by PCR-RFLP method, are considered as sensitive. But, Identification of 
sensitive and resistant strains by using real-time PCR method was based on the 
determination of sensitive strains. In the first step, determination of sensitive, resistance and 
mix of sensitive and resistance strains were done and in the next step, determination of 
mutations types in resistance and mix strains were done, that leading to accurate diagnosis 
of the resistant and sensitive strains. 
Based on the patterns of competitive growth as well as the individual growth of different 
clarithromycin resistance mutant strains, Wang and colleagues conclude that the order of 
preference of competitive accumulation is A2142G A2143G A2142C A2143C (A2142T). If the 
same is true in vivo, once an A-to-G transient mutation occurs (spontaneously or drug 
induced), the other types of mutation that exist in the same environment, if any, are likely to 
be overgrown after a period of time. A-to-C or A-to-T mutants could be isolated only when 
an A-to-G mutant has not appeared at that particular gastric niche. Their results provide a 
rational explanation for the mutation pattern observed in clinical isolates [13]. These results 
are confirmed by Van der Ende and coworkers and discussed that the growth rates of H. 
pylori isolates with the A21423G, A21423C, or A21433G mutation did not differ from that of 
the wild type, but H. pylori isolates with other 23S rDNA mutations grew more slowly [11].  
Based on two opinions, we used real-time PCR for simultaneous identification of H. pylori, 
Clarithromycin resistance point mutations and direct quantification of gastric mucosal 
density in order to answer to this question; why some clarithromycin resistance point 
mutations are more prevalent than other mutations. At first; Wang described an additional 
possible mechanism yet to be identified, by which the A-to-G mutations are preferentially 
produced in H. pylori, may also contribute to the observed predominance of A-to-G 
mutations [13]. Second; Van der Ende [11] described that; If only a single colony from the 
primary H. pylori populations is used to test for clarithromycin susceptibility, the results can 
be misinterpreted. Assessment of 23S rRNA mutations in H. pylori directly from biopsy 
specimens by molecular biological techniques has the advantage that infection with a mixed 
H. pylori population is easily detected. In addition, knowledge of the type of 23S rRNA 
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mutation may be important since clarithromycin MICs are associated with the type of 23S 
rRNA mutation in H. pylori [11]. 
Several studies which done by Pina [34], Marais [28] and Russmann [36] in Europe revealed 
that A2144G, A2143G and A2143C were more prevalent in Europe respectively. However, 
the current study showed that A2143G, A2142G, A2143C and A2144G were more prevalent 
mutation in Iran respectively. Our data showed that wild type strains more related to 106 to 
107 bacteria in gastric biopsy specimens of patients. Also, strains with clarithromycin 
resistance mutation assessed in this study are significantly related to 106 in gastric biopsy 
which are equal to density of wild type strain. This data revealed that these mutated strains 
has a same growth rate to wild type, preferentially produced in populations and selected by 
natural selection force and they can exist and distributed in H. pylori population 
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